EQL Pharma ABOSTO:EQL -2.10%42 EBIT per Share is kr1.63 as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 810 Drug Manufacturers companies, EQL Pharma AB ranks worse than 54.57% on this metric.
EQL Pharma AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr0.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr1.63.
During the past 12 months, the average EBIT per Share Growth Rate of EQL Pharma AB was -28.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 5.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 27.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for EQL Pharma AB's EBIT per Share or its related term are showing as below:
OSTO:EQL'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8 Med: 30.55 Max: 133.7
Current: 5.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of EQL Pharma AB was 133.70% per year. The lowest was -8.00% per year. And the median was 30.55% per year.
OSTO:EQL's 3-Year EBIT Growth Rate is ranked worse than 54.57% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.55
vs OSTO:EQL: 5.10
EQL Pharma AB's EBIT for the
three
months ended in Mar. 2026 was kr5.1 Mil.
EQL Pharma AB (OSTO:EQL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
EQL Pharma AB EBIT per Share Related Terms
EQL Pharma AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.63
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a EBIT per Share of kr1.63 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #442 out of 810 companies in the Drug Manufacturers industry, placing it in the top 54.6%.
Is EQL Pharma AB's EBIT per Share too high?
EQL Pharma AB's current EBIT per Share is kr1.63. Based on the distribution chart, EQL Pharma AB ranks #442 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #442 out of 810 companies for EBIT per Share. This places EQL Pharma AB in the lower half of its industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current EBIT per Share is kr1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current EBIT per Share of kr1.63. The current EBIT per Share is kr1.63. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EBIT per Share is kr1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
